Abraxis Oncology. (June 2006).AbraxaneTM (paclitaxel powder for injectable suspension, nanoparticle, albumin-bound (nab) paclitaxel) [Package Monograph]. Richmond Hill, ON Canada.


Almadrones, L.A., & Arcot, R. (1 g9g). Patient guide to peripheral neuropathy. Oncology Nursing Forum, 26,1 359-1 362.


American BioSciences, Inc. (2004). Data on file.


Armstrong,T.A., Almadrones, L., & Gilbert, M. (2005).Chemotherapy-induced peripheral neuropathy. Onco/ogy Nursing Forum, 32, 305-311.


Blerkerot, P. (2005). Discovering nanothechnology and metastatic breast cancer: new treatment options. Lecture; Hyatt Regency Phoenix Hotel, 11/12/2005.


BIum,J.L., Savin, MA., Edelman, G., Pippen,J.E., Robert, N., Sandbach,J., et al. (2004). Longterm disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [Abstract]. Journal of Clinical Oncology, 22 (Suppl. 14S), 543.Abstract No.543.


Brandt, J.M. (1998). Cancer-related neuropathic pain. Nurse Practitioner Forum, 9, 154-162.


Bristol-Myers Squibb. (2005).Taxol® (paclitaxel) [Package Insert]. Princeton, NJ:Authors.


Pellegrini, F. & Budman, DR. (2005).Tubulin function:Action of tubulins for drug development. Cancer


Investigations, 23, 264-273.


Cancer Therapy Evaluation Program. (2003). Common terminology criteria for adverse events.Version 3.0,


DCTD, NCI, NIH, DHHS. Retrieved September 15, 2005, from http://ctep.cancer.gov.


Desai, N.,Trieu,V.,Yao, R., Franke,T., & Soon-Shiong, P. (2004a, December). SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. [Abstract]. San Antonio Breast Cancer Symposium. Retrieved March 14, 200S, from http://www.

abstracts2view/sabcs.Abstract No. 206.


Desai, N.,TrieuV. ,Yao, R., Labao, E., & Soon-Shiong, P (2004b, December). Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (ABI­007) by gp6O-receptors:A pathway inhibited by taxol. [Abstract]. San Antonio Breast Cancer Symposium. Retrieved March 14, 2005, from

httg~//www.abstracts2view/sabcs. Abstract No. 1071.


Desai, N.,Yao, Z., Soon-Shiong, R, & Dykes, D. (2002). Evidence of enhanced in vivo efficacy at maximum tolerated dose (MID) of nanoparticle paclitaxel (ABI­007) and taxol in 5 human tumor xenografts of varying sensitivity to paclitaxel [Abstract]. Proceedings American Society for Clinical Oncology, 21, 462. Abstract No.462.


Fan,W, Sui, M., & Huang,Y. (2004). Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: Mechanisms


and its clinical impact. Current Medicinal Chemistry, II, 403-411.


Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer, 5, 161-I 71.


John,T.A.,Vogel, S.M.,Tiruppathi, C., Malik,A.B., & Minshall, RD. (2003). Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. American Journal Physiology Lung Cellular and Molecular Physiology 284, LI 87- 196.


Grupo Grifols de American, Inc. (1998). Human Albumin Grifols® [Package Insert]. Barcelona, Spain:Authors.


Jemal,A., Murray,T.,Ward, E., Samuels,A.,Tiwari, R.C,, Ghafoor,A., etal. (2005). Cancer statistics, 200S. CA Cancer Journalfor Clinicians, 55, 10-30.


Kloover,J.S., den Bakker, MA., Gelderblom, H., & van Meerbeeck,J.R (2004). Fatal outcome of a hypersensitivity reaction to paclitaxel:A critical review of premedication regimens. British Journal of Cancer, 90,304-305.


Mielke, S., Sparreboom,A., Steinberg, SM., Gelderblom, H., Unger, C., Behringer, et al. (2005).Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clinical Cancer Research, Il, 4843-4850.


Moghimi, SM., Hunter,A.C., & Murray,J.C. (2005). Nanomedicine: Current status and future prospects.

Federation ofAmerican Societies for Experimental Biolog— 19, 3 11-330.


Nabholtz,J.M.,Tonkin, K., Smylie, M,,Au, H.]., Lindsay, MA., & Mackey,J. (2000). Chemotherapy of breast cancer:

are the taxanes going to change the natural history of breast cancer? Expert Opinion on Pharmacotherapy, 1,187-206.


NanoBusiness Alliance. (2004). NanoBusiness Alliance [Website]. Retrieved September21, 2005, fromhttp://nanobusiness.org.


National Cancer Institute, (2004). Nanodevices. Retrieved August 10, 2005, from http://www.cancer.gov/ cancertopics/understandingcancer/nanodevices


National Cancer Institute. (2004), Understanding Cancer Series: Nanodevices. Retrieved August 29, 2005, from http:Ilwww.nci. nih.gov/cancertopicslunderstandingcancerlnanodevices.


National Comprehensive Cancer Network. (2004). Clinical practice guidelines in oncologylM. Breast cancer, VI .2004. Jenkintown, PA: Authors.


Nguyen,V.H., & Lawrence, H.]. (2004). Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. Journal of Clinical Oncology, 22, 1767-1769.


Nuijen, B. (2004). Pharmaceutical formulation of novel anticancer agents. In DR. Budman,A.H. Calved, & E.K.Rowinsky (Eds.), Handbook of anticancer drug development (pp.205-223). Philadelphia, PA: Lippincott Williams &



O’Shaughnessy,J.,Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Hawkins, M.J., & Gradishar,W.J. (2003, December).ABI-007 (ABRAXANE ), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: a phase Ill trial. [Abstract]. San Antonio Breast Cancer Symposium. Retrieved March 11,2005, from http:I/www.abstracts2view.comlbcsO3.Abstract No.44.


O’Shaughnessy J.A., Blum J.L., Sandbach J.F., Savin M., Fenske B., & Hawkins M.J. (2004).Weekly nanoparticle albumin paclitaxel (nab-paclitaxel) results in

long-term disease control in patients with taxane-refractory metastatic breast cancer. [Abstract]. San Antonio Breast Cancer Symposium. Retrieved March 18,

2005 from http: http://www.abstracts2view.com/sabcs.Abstract No. 1070.


Seidman,A.D. (2001 ).The evolving role of gemcitabine in the management of metastatic breast cancer, Retrieved March 5, 2005, from www.medscape.com/viewarticle/4525328.


Szebeni,J., Fontana,J.L.,Wassef, N.M., Mongan, PD., Morse, OS., Dobbins. D.E.,et al. (1999). Hemodynamic changes induced by liposomes and liposome­encapsulated hemoglobin in pigs:A model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti­C5a antibody. Circulation, 99, 2302-2309.


Winer, ER, Berry, D.A.,Woolf. S., Duggan, D., Kornblith,A., Harris, L.N., et al. (2004). Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.Journal of Clinical Oncology, 22, 2061-2068.


Van Zuylen, L.,Verweij,J.,& Sparreboom,A. (2001). Role of formulation vehicles in taxane pharmacology, Investigational New Drugs, 19, 125-141.


Vogel CL., & Nabholtz J.M. (1999). Monotherapy of metastatic breast cancer:A review of newer agents. Oncologist, 4, 17-33.


Wilkes, G.M., & Barton-Burke, M. (2005). Oncology nursing drug handbook. Sudbury, MA: Jones and Bartlett Publishers.


Wilkes, G.M. (2003). Neurologic disturbances: Peripheral neuropathy. In C.M.Yarbro, M.H. Frogge, & M. Goodman (Eds.), Cancer symptom management (3rd ed., pp.77-96). Sudbury, MA: Jones and Bartlett.